Effect of Compound Danshen Dripping Pills on cardiac function after acute anterior ST-segment elevation myocardial infarction: A randomized trial

Abstract

The current study aimed to evaluate the efficacy and safety of Compound Danshen Dripping Pills (CDDP) in improving cardiac function in patients with acute anterior ST-segment elevation myocardial infarction (AAMI). Between February 2021 and February 2023, 247 eligible patients with AAMI after primary percutaneous coronary intervention were enrolled and randomly assigned (1∶1) to receive CDDP (n = 126) or placebo (n = 121), with a follow-up of 48 weeks. Compared with the placebo group, the CDDP group demonstrated a significant increase in left ventricular ejection fraction values after 24 weeks of treatment (least squares mean: 3.31; 95% confidence interval [CI]: 1.72-4.90; P < 0.001) and at the 48-week follow-up (least squares mean: 4.35; 95% CI: 2.76-5.94; P < 0.001). Significant reductions in N-terminal pro-B-type natriuretic peptide levels were observed in both groups at the 24- and 48-week visits with no significant difference between the two groups (P > 0.1 for all). The incidence of major adverse cardiovascular and cerebrovascular events was 6.35% in the CDDP group and 5.79% in the placebo group (P = 0.822). Notably, no serious adverse events were attributed to CDDP. These findings suggest that CDDP may be well tolerated and could improve left ventricular ejection fraction in patients with AAMI at 24 and 48 weeks.

Keywords

Compound Danshen Dripping Pills / cardiac function / acute anterior myocardial infarction / randomized controlled trial

Fundings

This work was supported by Tasly Pharmaceutical Group Co., Ltd. (Grant No. 303100031BA20). This investigator-initiated trial was designed and conducted independently by the authors. Data collection was managed by independent data recorders at each participating center. The funding body did not interfere with the study design, data analysis, interpretation of results, or manuscript preparation.

Acknowledgments

The authors gratefully acknowledge all of the study centers involving recruiting patients and completing follow-up visits. We also thank Tasly Pharmaceutical Group Co., Ltd. for providing information about CDDP.

References

[1] Bhatt AS, Ambrosy AP, Velazquez EJ. Adverse remodeling and reverse remodeling after myocardial infarction[J]. Curr Cardiol Rep, 2017, 19(8): 71. doi: 10.1007/s11886-017-0876-4

[2] Sackner-Bernstein JD. The myocardial matrix and the development and progression of ventricular remodeling[J]. Curr Cardiol Rep, 2000, 2(2): 112-119. doi: 10.1007/s11886-000-0007-4

[3] Swirski FK, Nahrendorf M. Cardioimmunology: The immune system in cardiac homeostasis and disease[J]. Nat Rev Immunol, 2018, 18(12): 733-744. doi: 10.1038/s41577-018-0065-8

[4] Bolognese L, Neskovic AN, Parodi G, et al. Left ventricular remodeling after primary coronary angioplasty: Patterns of left ventricular dilation and long-term prognostic implications[J]. Circulation, 2002, 106(18): 2351-2357. doi: 10.1161/01.CIR.0000036014.90197.FA

[5] Deng H, Zou J, Wang N, et al. Nicorandil alleviates cardiac remodeling and dysfunction post-infarction by up-regulating the nucleolin/autophagy axis[J]. Cell Signal, 2022, 92: 110272. doi: 10.1016/j.cellsig.2022.110272

[6] Naseratun N, Kobara M, Watanabe Y, et al. Comparison of effects of L/N-type and L-type calcium channel blockers on post-infarct cardiac remodelling in spontaneously hypertensive rats[J]. Clin Exp Pharmacol Physiol, 2020, 47(9): 1545-1553. doi: 10.1111/1440-1681.13329

[7] Udell JA, Petrie MC, Jones WS, et al. Left ventricular function, congestion, and effect of empagliflozin on heart failure risk after myocardial infarction[J]. J Am Coll Cardiol, 2024, 83(23): 2233-2246. doi: 10.1016/j.jacc.2024.03.405

[8] Yang Y, Feng K, Yuan L, et al. Compound Danshen Dripping Pill inhibits hypercholesterolemia/atherosclerosis-induced heart failure in ApoE and LDLR dual deficient mice via multiple mechanisms[J]. Acta Pharm Sin B, 2023, 13(3): 1036-1052. doi: 10.1016/j.apsb.2022.11.012

[9] Xu H, Wang D, Peng C, et al. Rabbit sera containing Compound Danshen Dripping Pill attenuate leukocytes adhesion to TNF-alpha—activated human umbilical vein endothelial cells by suppressing endothelial ICAM-1 and VCAM-1 expression through NF-kappaB signaling pathway[J]. J Cardiovasc Pharmacol, 2014, 63(4): 323-332. doi: 10.1097/FJC.0000000000000046

[10] Guo J, Yong Y, Aa J, et al. Compound Danshen dripping pills modulate the perturbed energy metabolism in a rat model of acute myocardial ischemia[J]. Sci Rep, 2016, 6: 37919. doi: 10.1038/srep37919

[11] Frantz S, Hundertmark MJ, Schulz-Menger J, et al. Left ventricular remodelling post-myocardial infarction: Pathophysiology, imaging, and novel therapies[J]. Eur Heart J, 2022, 43(27): 2549-2561. doi: 10.1093/eurheartj/ehac223

[12] Zou H, Zhang B, Xu X, et al. Urinary metabolomic strategy to evaluate Compound Danshen Dripping Pills for myocardial ischaemia in rats[J]. J Pharm Biomed Anal, 2015, 112: 98-105. doi: 10.1016/j.jpba.2015.04.033

[13] Wu Y, Deng B, Wang S, et al. Effects of compound Danshen dripping pills on ventricular remodeling and cardiac function after acute anterior wall ST-segment elevation myocardial infarction (CODE-AAMI): Protocol for a randomized placebo-controlled trial[J]. Chin J Integr Med, 2023, 29(12): 1059-1065. doi: 10.1007/s11655-023-3648-6

[14] Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. 2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction[J]. Chin J Cardiol, 2019, 47(10): 766-783.

[15] Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit[J]. Am J Cardiol, 1967, 20(4): 457-464. doi: 10.1016/0002-9149(67)90023-9

[16] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247. doi: 10.1016/j.ejca.2008.10.026

[17] Chen L, Zhang M, Li C, et al. Effects of radix salviae miltiorrhizae cardiotonic pills on adhesion factors in atherosclerotic rabbits[J]. Chin J Arterioscler, 2007, 15(2): 101-104.

[18] Shabbir A, Zisa D, Suzuki G, et al. Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: A noninvasive therapeutic regimen[J]. Am J Physiol Heart Circ Physiol, 2009, 296(6): H1888-H1897. doi: 10.1152/ajpheart.00186.2009

[19] Li G, Zheng X, Wang H, et al. Multicenter investigation of Compound Danshen Dripping Pills on short-term clinical events in patient with ST elevation myocardial infarction undergoing primary PCI (MICD-STEMI PCI)[J]. Chin J Intervent Cardiol, 2011, 19(1): 24-28.

[20] Fu W. Effect of Compound Danshen Dripping Pills on BNP level and ventricular remodeling in patients with acute myocardial infarction after PCI[J]. J Shanxi Med Col Continuing Educ, 2019, 29(4): 54-56. (in Chinese)

[21] Shi F. Effects of Compound Danshen Dripping Pills on serum inflammatory factors and ventricular remodeling in patients with acute myocardial infarction[J]. Chin J Geriatric Care, 2019, 17(1): 74-76. (in Chinese)

[22] Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment[J]. Clin Endocrinol, 1997, 47(3): 287-296. doi: 10.1046/j.1365-2265.1997.2361058.x

[23] Lee KK, Doudesis D, Anwar M, et al. Development and validation of a decision support tool for the diagnosis of acute heart failure: Systematic review, meta-analysis, and modelling study[J]. BMJ, 2022, 377: e068424.

[24] Armstrong PW, Zheng Y, Troughton RW, et al. Sequential evaluation of NT-proBNP in heart failure: Insights into clinical outcomes and efficacy of vericiguat[J]. JACC Heart Fail, 2022, 10(9): 677-688. doi: 10.1016/j.jchf.2022.04.015